The early humoral immune response toBacillus anthracistoxins in patients infected with cutaneous anthrax
Open Access
- 1 July 2011
- journal article
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 62 (2), 164-172
- https://doi.org/10.1111/j.1574-695x.2011.00800.x
Abstract
Bacillus anthracis, the causative agent of anthrax, produces a tripartite toxin composed of two enzymatically active subunits, lethal factor (LF) and edema factor (EF), which, when associated with a cell-binding component, protective antigen (PA), form lethal toxin and edema toxin, respectively. In this preliminary study, we characterized the toxin-specific antibody responses observed in 17 individuals infected with cutaneous anthrax. The majority of the toxin-specific antibody responses observed following infection were directed against LF, with immunoglobulin G (IgG) detected as early as 4 days after the onset of symptoms in contrast to the later and lower EF- and PA-specific IgG responses. Unlike the case with infection, the predominant toxin-specific antibody response of those immunized with the US anthrax vaccine absorbed and UK anthrax vaccine precipitated licensed anthrax vaccines was directed against PA. We observed that the LF-specific human antibodies were, like anti-PA antibodies, able to neutralize toxin activity, suggesting the possibility that they may contribute to protection. We conclude that an antibody response to LF might be a more sensitive diagnostic marker of anthrax than to PA. The ability of human LF-specific antibodies to neutralize toxin activity supports the possible inclusion of LF in future anthrax vaccines.Keywords
This publication has 41 references indexed in Scilit:
- Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect againstBacillus anthracisInfection and Enhance Endogenous Immunity to AnthraxInfection and Immunity, 2007
- An Anthrax Lethal Factor-Neutralizing Monoclonal Antibody Protects Rats before and after Challenge with Anthrax ToxinInfection and Immunity, 2005
- Protective Antigen and Toxin Neutralization Antibody Patterns in Anthrax Vaccinees Undergoing Serial PlasmapheresisClinical and Vaccine Immunology, 2005
- Characterization of the human immune response to the UK anthrax vaccineFEMS Immunology & Medical Microbiology, 2004
- In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activityJournal of Antimicrobial Chemotherapy, 2004
- The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteriaNature, 2003
- Fate of germinated Bacillus anthracis spores in primary murine macrophagesMolecular Microbiology, 2001
- Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ‐induced release of NO and TNFαFEBS Letters, 1999
- Germination of Bacillus anthracis spores within alveolar macrophagesMolecular Microbiology, 1999
- Role of the Lymphatics in the Pathogenesis of AnthraxThe Journal of Infectious Diseases, 1965